AKT1 quiescent cancer cells in ductal carcinoma in situ of the breast.

TitleAKT1 quiescent cancer cells in ductal carcinoma in situ of the breast.
Publication TypeJournal Article
Year of Publication2019
AuthorsKabraji S, Sole X, Huang Y, Bango C, Sgroi D, Loda M, Ramaswamy S
JournalNPJ Breast Cancer
Volume5
Pagination10
Date Published2019
ISSN2374-4677
Abstract

Ductal carcinoma in situ (DCIS) of the breast precedes the development of invasive breast cancer and reflects the genomic changes and protein expression profile of invasive disease. AKT1 cancer cells (QCC) are a rare, drug-tolerant, epigenetically plastic, and quiescent cancer cell subset that we previously identified at a frequency of 0.5-1% in primary breast tumors using the marker profile: AKT/H3K9me2/HES1. Here we used quantitative immunofluorescence microscopy with computational image analysis to show that AKT1 QCCs are present in DCIS from patients with and without co-existing invasive breast cancer. These data suggest that a drug-resistant, quiescent cancer cell state is present in premalignant breast lesions prior to the development of invasive disease. These findings warrant further study of whether AKT1 QCCs contribute to invasive tumor development and recurrence, similar to their role in more advanced malignancy.

DOI10.1038/s41523-019-0105-y
Alternate JournalNPJ Breast Cancer
PubMed ID30911675
PubMed Central IDPMC6428812
Grant ListR01 CA185086 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Category:

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700